KEGG   DRUG: Linvoseltamab
Entry
D12222                      Drug                                   
Name
Linvoseltamab (USAN);
Linvoseltamab (genetical recombination) (JAN);
Linvoseltamab-gcpt;
Lynozyfic (TN)
Formula
C6455H9955N1721O2039S47
Exact mass
145708.5068
Mol weight
145798.56
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NFWMTWVRQA PGKGLEWVAN MNQDGSEKYY
VDSVKGRFTI SRDNAKSSLY LQMNSLRAED TAVYYCARDR EYCISTSCYD DFDYWGQGTL
TVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA
LQSSGLYSL SSVVTVPSSS LGTKTYTCNV DHKPSNTKVD KRVESKYGPP CPPCPAPPVA
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI SKAKGQPREP QVYTLPPSQE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSRLTVDKSR
WQEGNVFSCS VMHEALHNHY TQKSLSLSLG K
(heavy chain)
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYSMHWVRQA PGKGLEWVSG ISWNSGSKGY
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCAKYG SGYGKFYHYG LDVWGQGTTV
TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV
LQSSGLYSLS SVVTVPSSSL GTKTYTCNVD HKPSNTKVDK RVESKYGPPC PPCPAPPVAG
PSVFLFPPKP KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLPPSQEE
MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SRLTVDKSRW
QEGNVFSCSV MHEALHNRFT QKSLSLSPGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCRASQSIS SYLNWYQQKP GKAPKLLIYA ASSLQSGVPS
RFSGSGSGTD FTLTISSLQP EDFATYYCQQ SYSTPPITFG QGTRLEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(Disulfide bridge: H22-H96, H103-H108, H139-L215, H152-H208, H231-h230, H234-h233, H265-H325, H371-H429, h22-h96, h138-L'215, h151-h207, h264-h324, h370-h428, L23-L88, L135-H195, L723-L'88, L'135-L'195)
  Type
Peptide
Remark
ATC code: L01FX37
Efficacy
Anti-TNFRSF17 antibody
  Disease
Multiple myeloma [DS:H00010]
  Type
Monoclonal antibody
Comment
Treatment of plasma cell disorders
Target
TNFRSF17 (BCMA, CD269) [HSA:608] [KO:K05153]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04672  Intestinal immune network for IgA production
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX37 Linvoseltamab
      D12222  Linvoseltamab (USAN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Anti-CD3/BCMA Antibodies
    Linvoseltamab
     D12222  Linvoseltamab (USAN)
Target-based classification of drugs [BR:br08310]
 Signaling molecules and receptors
  Cytokine receptors
   Tumor necrosis factor receptors
    TNFRSF17 (BCMA, CD269)
     D12222  Linvoseltamab (USAN)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12222
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12222
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12222
Other DBs
CAS: 2408319-25-3
PubChem: 497620635
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system